Targeting super-enhancers to regulate HIV transcription and latency

Active Grant Awarded

Award ID
R21AI203697
Recipient
Awarding agency
Obligated
$297,000

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 13% complete
Place of performance
San Antonio, TX 78227, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, awarded Texas Biomedical Research Institute $297,000 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds Grant R21AI203697, "Targeting Super-Enhancers to Regulate HIV Transcription and Latency." The project will define the molecular mechanisms by which super-enhancer-associated long non-coding RNA SEA regulates INTS1 gene transcription, and it will functionally characterize a network of super-enhancer lncRNAs that govern HIV transcription and latency. The underlying hypothesis is that selective disruption of these RNAs can reverse HIV latency. The recipient does business as Southwest Foundation for Biomedical Research. Performance runs through August 31, 2028, at San Antonio, TX 78227, USA.

Description

Abstract
Although antiretroviral therapy (art) effectively suppresses viremia, human immunodeficiency virus (HIV) persists in long-lived latent reservoirs, primarily within resting CD4⁺ T cells. These transcriptionally silent but replication-competent proviruses evade immune clearance and drive rapid viral rebound upon treatment interruption, necessitating lifelong art. Intermittent viral transcription from these reservoirs also contributes to chronic immune activation and HIV-associated comorbidities. A major barrier to achieving a functional cure is the incomplete understanding of host regulatory mechanisms that maintain or release HIV latency. Current latency-reversing agents (LRAS) lack specificity and potency and often induce global immune activation, underscoring the need for precise, host-directed strategies to selectively reactivate latent HIV. Long non-coding rnas (LNCRNAS), particularly super-enhancer-associated LNCRNAS (SE-LNCRNAS), are emerging as critical regulators of transcriptional programs. Our preliminary data show that HIV infection modulates a subset of SE-LNCRNAS in CD4⁺ T cells and that targeted silencing of specific SE-LNCRNAS enhances HIV transcription. We identified a novel SE-lncrna (sea; ENSG00000273230) that regulates integrator complex subunit 1 (INTS1) expression. INTS1 is a component of the integrator complex that represses including HIV transcription. These findings suggest that SE-LNCRNAS form host regulatory circuits that actively maintain HIV latency. We hypothesize that SE-LNCRNAS control HIV transcription and latency by scaffolding transcriptional regulators at viral and cellular loci, and that selective disruption of these rnas can reverse latency. To test this hypothesis, we will (1) define the molecular mechanisms by which sea regulates INTS1 gene transcription and (2) functionally characterize a network of SE-LNCRNAS that governs HIV transcription and latency. Aim 2 will use pooled single-cell RNA perturbation to identify and prioritize additional SE-LNCRNAS with reproducible effects on HIV transcription. Together, these studies will define a new class of host regulators of HIV transcription and latency and provide a foundation for future mechanistic and translational studies.

Quick answers

Who received award R21AI203697?

R21AI203697 was awarded to Texas Biomedical Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 19, 2026.

How much is award R21AI203697 worth?

$297,000 has been obligated on R21AI203697.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award